Clinical Trial Update: BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating BCMA-targeted bispecific antibody therapy for multiple myeloma patients who relapse after BCMA CAR T-cell therapy; the study i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• BCMA bispecific antibody therapy

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Multiple Myeloma | Phase 2 | Status: NOT_YET_RECRUITING